CHARACTERISTICS OF PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS) IN THE ILD-PRO REGISTRY

被引：0
|
作者：
Lobo, Leonard
Liu, Yi
Li, Peide
Ramaswamy, Murali
Swaminathan, Aparna
Veeraraghavan, Srihari
Fan, Yanni
Neely, Megan L.
Palmer, Scott M.
Olson, Amy L.
机构：
来源：
CHEST | 2023年 / 164卷 / 04期
关键词：
D O I：
10.1016/j.chest.2023.07.2004
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：3056A / 3057A
页数：2
相关论文
共 50 条
  • [41] Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
    Albera, Carlo
    Verri, Giulia
    Sciarrone, Federico
    Sitia, Elena
    Mangiapia, Mauro
    Solidoro, Paolo
    BIOMEDICINES, 2021, 9 (09)
  • [42] The natural history of progressive fibrosing interstitial lung diseases
    Martin Kolb
    Martina Vašáková
    Respiratory Research, 20
  • [43] Nintedanib in Progressive Fibrosing Interstitial Lung Diseases Reply
    Flaherty, Kevin R.
    Wells, Athol U.
    Brown, Kevin K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (08): : 781 - 781
  • [44] The natural history of progressive fibrosing interstitial lung diseases
    Brown, Kevin K.
    Martinez, Fernando J.
    Walsh, Simon L. F.
    Thannickal, Victor J.
    Prasse, Antje
    Schlenker-Herceg, Rozsa
    Goeldner, Rainer-Georg
    Clerisme-Beaty, Emmanuelle
    Tetzlaff, Kay
    Cottin, Vincent
    Wells, Athol U.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
  • [45] Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
    Chen, Xianqiu
    Guo, Jian
    Yu, Dong
    Jie, Bing
    Zhou, Ying
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] The Burden of Progressive-Fibrosing Interstitial Lung Diseases
    Cottin, Vincent
    Teague, Rhiannon
    Nicholson, Lindsay
    Langham, Sue
    Baldwin, Mike
    FRONTIERS IN MEDICINE, 2022, 9
  • [47] Nintedanib for treating progressive fibrosing interstitial lung diseases
    Adler, Amanda, I
    Guo, Yelan
    Thiam, Aminata
    Elliott, Nicole
    Patel, Sanjeev
    LANCET RESPIRATORY MEDICINE, 2021, 9 (12): : E116 - E117
  • [48] SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs)
    Paluch, Peter
    Sterclova, Martina
    Brabcova, Irena
    Viklicky, Ondrej
    Vasakova, Martina
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [49] Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
    Koschel, D.
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S. L. F.
    Kolb, M.
    Moua, T.
    Stowasser, S.
    Goeldner, R. G.
    Schlenker-Herceg, R.
    Brown, K. K.
    PNEUMOLOGIE, 2021, 75 : S30 - S31
  • [50] Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
    Dellaripa, Paul
    Aringer, Martin
    Mann-Vold, Anna Maria Hoff
    Kelly, Clive
    Mittoo, Shikha
    James, Alexandra
    Rohr, Klaus
    Stowasser, Susanne
    Inoue, Yoshikazu
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345